The protein drug Endostar, a recombinant form of human endostatin, received approval from China’s State Food and Drug Administration in 2005 for the treatment of non-small cell lung cancer [18], highlighting the potential efficacy of endostatin in cancer therapy. Here, COL18A1 is linked to non-small cell lung carcinoma.